Dr. Ledermann on Systemic Treatment for Rare Gynecologic Tumors

Jonathan Ledermann, MD
Published: Wednesday, Dec 27, 2017



Jonathan Ledermann, MD, professor of medical oncology, UCL Cancer Institute, London, United Kingdom, discusses systemic treatment for patients with rare gynecologic tumors.

Rare tumors are the hardest ones to treat because less is understood about their biology and the current drugs are not as active in these tumors, explains Ledermann.

In order to understand the management of rare epithelial tumors, global collaborative studies are needed, says Ledermann.



Jonathan Ledermann, MD, professor of medical oncology, UCL Cancer Institute, London, United Kingdom, discusses systemic treatment for patients with rare gynecologic tumors.

Rare tumors are the hardest ones to treat because less is understood about their biology and the current drugs are not as active in these tumors, explains Ledermann.

In order to understand the management of rare epithelial tumors, global collaborative studies are needed, says Ledermann.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Redefining Ovarian Cancer Treatment Paradigms by Maximizing Therapeutic Outcomes with PARP InhibitorsSep 29, 20182.0
Community Practice Connections™: 1st Annual School of Nursing Oncology™Oct 31, 20181.5
Publication Bottom Border
Border Publication
x